Other
Accrued liabilities
Gilead Sciences Accrued liabilities decreased by 186.6% to -$702.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 187.7%, from -$244.00M to -$702.00M. Over 2 years (FY 2021 to FY 2024), Accrued liabilities shows a downward trend with a -60.4% CAGR.
Analysis
StatementIncome Statement
SectionOther
CategoryLiquidity
SignalContext dependent
VolatilityStable
First reportedQ1 2013
Last reportedQ1 2026May 7, 2026
How to read this metric
Fluctuations reflect changes in the timing of operational expense recognition and payment cycles.
Detailed definition
This represents the net change in short-term obligations for expenses that have been incurred but not yet invoiced or pa...
Peer comparison
Standard line item in the operating section of the cash flow statement.
Metric ID:
other_increase_decrease_in_accrued_liabilitiesHistorical Data
16 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $25.00M | -$138.00M | $1.54B | -$1.66B | -$543.00M | $634.00M | $50.00M | $317.00M | -$175.00M | -$174.00M | $152.00M | $305.00M | -$244.00M | -$166.00M | $811.00M | -$702.00M |
| QoQ Change | — | -652.0% | >999% | -207.6% | +67.2% | +216.8% | -92.1% | +534.0% | -155.2% | +0.6% | +187.4% | +100.7% | -180.0% | +32.0% | +588.6% | -186.6% |
| YoY Change | — | — | — | — | +67.2% | — | — | — | +67.8% | -127.4% | +204.0% | -3.8% | -39.4% | +4.6% | +433.6% | -187.7% |
Range-$1.66B – $1.54B
CAGR+143.4%
Avg YoY Growth+46.5%
Median YoY Growth+4.6%
Accrued liabilities at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's accrued liabilities?
- Gilead Sciences (GILD) reported accrued liabilities of -$702.00M in Q1 2026.
- How has Gilead Sciences's accrued liabilities changed year-over-year?
- Gilead Sciences's accrued liabilities decreased by 187.7% year-over-year, from -$244.00M to -$702.00M.
- What is the long-term trend for Gilead Sciences's accrued liabilities?
- Over 2 years (2021 to 2024), Gilead Sciences's accrued liabilities has grown at a -60.4% compound annual growth rate (CAGR), from $689.00M to $108.00M.
- What does accrued liabilities mean?
- The net change in short-term obligations for expenses incurred but not yet paid.